Abzena

Abzena is a leading end-to-end bioconjugate and complex biologics CDMO + CRO, providing comprehensive support from discovery to commercial launch. The company offers fully integrated programs and individual services to de-risk and streamline the development of new treatments for patients. Abzena's tailored strategies and innovative solutions enable biotech and biopharma companies to expedite the development of potential medicines. With research, development, and cGMP facilities in San Diego, CA, Bristol, PA, and Cambridge, UK, Abzena is well-positioned geographically. Established in 2001, the company operates in the Biopharma, Biotechnology, and Pharmaceutical industries, with its headquarters in the United States.

The latest investment of $65.00M from Private Equity Round on 31 March 2022 was led by Biospring Partners and Welsh, Carson, Anderson & Stowe. This substantial investment reflects confidence in Abzena's capabilities and potential for driving advancements in the biopharmaceutical space.